Lung Cancer Clinical Trial

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

Summary

A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors.

While recent research has identified SABR as a promising method to increase local control (LC) of lung cancer, further research has indicated that tumor volume is a prognostic factor, with increased size/volume of tumor being associated with poorer outcomes. This study explores if a volume-adapted strategy for the radiologic exposure (dose) will improve efficacy in larger tumors (ie, > 10 cc).

This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study of a specific drug or device.

View Eligibility Criteria

Eligibility Criteria

INCLUSION CRITERIA

Limited primary non-small cell lung cancers (NSCLC) (ie, graded as T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0), or metastatic lung tumors with no evidence of uncontrolled extrathoracic metastases.

Up to 4 lesions may be considered.

For a single lesion, the sum of three orthogonal diameters can be no more than 20 cm.
For multiple lesions, no lesion can have a sum of orthogonal diameters greater than 15 cm.
Both peripheral and central tumors are accepted for this trial.
Age ≥ 18 years old
Patients may be enrolled more than once (eg, for a new tumor lesion)

EXCLUSION CRITERIA

Contraindication for radiotherapy
Pregnant and breastfeeding women are excluded
If prior radiation therapy, there is no overlap with the prior high dose regions (EXCEPTION: by approval of the investigators).

Study is for people with:

Lung Cancer

Estimated Enrollment:

256

Study ID:

NCT01463423

Recruitment Status:

Completed

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Stanford University Cancer Institute
Stanford California, 94305, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States
Princess Margaret Cancer Center
Toronto Ontario, ON M5, Canada
Hokkaido University Hospital
Sapporo Hokkaido, , Japan

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

256

Study ID:

NCT01463423

Recruitment Status:

Completed

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider